. 2020 May 27;44(2):519–532. doi: 10.3892/or.2020.7626

Table III.

Association between the 8 circRNA expression levels and clinicopathological characteristics of the 45 PTC patients.

		chr5:161330882-161336769−		chr12:129699809-129700698−		chr9:22046750-22097364+		chr20:17456347-17465553+		chr7:116699070-116700284+		chr8:18765448-18804898−		chr7:22308338-22318037−		chr5:38523418-38530666−

Clinico-pathologic parameters	No. of cases (%)	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value	Mean ± SD	P-value
Age (years)
<45	28	1.21E-02±	0.797	2.26E-03±	0.574	4.34E-04±	0.386	1.52E-04±	0.708	2.39E-02±	0.761	2.13E-02±	0.374	8.81E-03±	0.963	8.12E-04±	0.673
	(62.2)	0.014		0.006		0.001		0.000		0.039		0.018		0.011		0.001
≥45	17	1.25E-02±		2.12E-03±		4.45E-04±		1.54E-04±		2.32E-02±		2.21E-02±		8.51E-03±		8.01E-04±
	(37.8)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
Sex
Female	33	1.29E-02±	0.209	2.06E-03±	0.259	4.47E-04±	0.472	1.57E-04±	0.590	2.37E-02±	0.505	2.26E-02±	0.228	8.61E-03±	0.878	7.99E-04±	0.342
	(73.3)	0.014		0.005		0.001		0.000		0.039		0.019		0.011		0.001
Male	12	1.12E-02±		2.26E-03±		4.33E-04±		1.56E-04±		2.47E-02±		2.08E-02±		9.05E-03±		8.61E-04±
	(26.7)	0.014		0.006		0.001		0.000		0.040		0.018		0.011		0.001
Multifocal
No	31	1.19E-02±	0.641	2.16E-03±	0.148	4.24E-04±	0.477	1.47E-04±	0.961	2.32E-02±	0.492	2.13E-02±	0.941	8.52E-03±	0.961	8.15E-04±	0.902
	(68.9)	0.013		0.005		0.001		0.000		0.039		0.018		0.011		0.001
Yes	14	1.29E-02±		2.06E-03±		4.47E-04±		1.57E-04±		2.37E-02±		2.26E-02±		8.61E-03±		7.99E-04±
	(31.1)	0.014		0.005		0.001		0.000		0.039		0.019		0.011		0.001
Ki67
<3	26	1.21E-02±	0.516	2.26E-03±	0.725	4.34E-04±	0.725	1.52E-04±	0.116	2.39E-02±	0.892	2.13E-02±	0.705	8.81E-03±	0.850	8.12E-04±	0.110
	(57.8)	0.014		0.006		0.001		0.000		0.039		0.018		0.011		0.001
≥3	15	1.29E-02±		2.06E-03±		4.47E-04±		1.57E-04±		2.37E-02±		2.26E-02±		8.61E-03±		7.99E-04±
	(33.3)	0.014		0.005		0.001		0.000		0.039		0.019		0.011		0.001
VEGF(+)
Yes	41
	(91.1)
No	0
pT-stage
x	1 (2.2)	2.24E-03	0.375	2.16E-03	0.590	4.53E-03	0.098	1.57E-04	0.381	2.35E-02	0.319	2.25E-02	0.754	8.66E-03	0.237	7.81E-04	0.037^a
1	29	1.25E-02±		2.12E-03±		4.45E-04±		1.54E-04±		2.32E-02±		2.21E-02±		8.51E-03±		8.01E-04±
	(64.4)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
2	4	1.22E-02±		2.21E-03±		4.32E-04±		1.50E-04±		2.36E-02±		2.16E-02±		8.67E-03±		7.94E-04±
	(8.9)	0.013		0.006		0.001		0.000		0.039		0.018		0.011		0.001
3	11	1.23E-02±		2.16E-03±		4.27E-04±		1.53E-04±		2.41E-02±		2.15E-02±		8.76E-03±		8.32E-04±
	(24.4)	0.014		0.005		0.001		0.000		0.040		0.018		0.011		0.001
pN stage
0/x	34	1.19E-02±	0.291	2.16E-03±	0.561	4.24E-04±	0.428	1.47E-04±	0.113	2.32E-02±	0.398	2.13E-02±	0.712	8.52E-03±	0.653	8.15E-04±	0.002^a
	(75.6)	0.013		0.005		0.001		0.000		0.039		0.018		0.011		0.001
1	11	1.27E-02±		2.16E-03±		4.53E-04±		1.57E-04±		2.35E-02±		2.25E-02±		8.66E-03±		7.81E-04±
	(24.4)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
BRAF mutation
Yes	36	1.27E-02±	0.015^a	2.16E-03±	0.865	4.53E-04±	0.041^a	1.57E-04±	0.955	2.35E-02±	0.496	2.25E-02±	0.036^a	8.66E-03±	0.670	7.81E-04±	0.444
	(80.0)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
No	9	9.71E-03±		1.95E-03±		3.96E-04±		1.38E-04±		2.14E-02±		1.75E-02±		8.59E-03±		7.24E-04±
	(20.0)	0.012		0.006		0.001		0.000		0.037		0.016		0.011		0.001
Capsular invasion
Yes	34	1.25E-02±	0.792	2.12E-03±	0.025^a	4.45E-04±	0.509	1.54E-04±	0.937	2.32E-02±	0.771	2.21E-02±	0.561	8.51E-03±	0.979	8.01E-04±	0.544
	(75.6)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
No	11	1.19E-02±		2.25E-03±		4.33E-04±		1.50E-04±		2.18E-02±		2.13E-02±		8.38E-03±		8.68E-04±
	(24.4)	0.014		0.006		0.001		0.000		0.037		0.018		0.011		0.001
With thyroiditis
Yes	9	1.27E-02±	0.610	2.16E-03±	0.061	4.53E-04±	0.222	1.57E-04±	0.364	2.35E-02±	0.570	2.25E-02±	0.212	8.66E-03±	0.395	7.81E-04±	0.281
	(20.0)	0.014		0.005		0.001		0.000		0.038		0.018		0.011		0.001
No	36	1.06E-02±		1.89E-03±		4.07E-04±		1.59E-04±		2.18E-02±		2.03E-02±		8.39E-03±		7.89E-04±
	(80.0)	0.013		0.006		0.001		0.000		0.039		0.019		0.011		0.001

Associations between the mean ± standard deviation of circRNA expression in the tumor and the clinical characteristics of the 45 PTC patients were analyzed with nonparametric statisticsMann-Whitney U test and Kruskal-Wallis test followed with post-hoc Dunn's multiple comparison test respectively for comparison between two or multiple groups, and P<0.05 was considered to indicate statistically significant differences. circRNA, circular RNA; PTC, papillary thyroid cancer; BRAF, B-type Raf kinase; SD, standard deviation.